Burden of migraine in Finland: health care resource use, sick-leaves and comorbidities in occupational health care

Table 5 The frequency (%) of comorbidities in controls and patients of the primary cohort

		Major depressive disorder, single episode	Major depressive disorder, recurrent	Other anxiety disorders	Reaction to severe stress, and adjustment disorders	Sleep disorders not due to a substance or known physiological condition	Acute sinusitis	Acute upper respiratory infections of multiple and unspecified sites	Acute bronchitis	Other and unspecified dorsopathies, not elsewhere classified	Dorsalgia
		F32	F33	F41	F43	F51	J01	J06	J20	M53	M54
Cohort	Control	7.1	2.5	7.9	9.9	8.8	25.2	52.2	17.9	14.3	31.4
	G43* primary cohort	13.0	4.8	14.1	17.4	17.4	38.0	71.7	26.0	28.6	46.8
	p-value	< 0.001	< 0.001	< 0.001	< 0.001	< 0.001	< 0.001	< 0.001	< 0.001	< 0.001	< 0.001
Primary cohort subgroups	No prescription	12.4	5.0	13.5	17.5	16.7	36.2	71.7	25.6	27.1	46.3
	Acute prescriptions	12.5	4.2	13.7	16.8	17.1	39.2	72.1	26.1	28.4	46.7
	Prophylactic prescription	17.1	5.9	17.5	18.8	20.6	41.2	70.4	27.3	35.6	49.1
	p-value	< 0.001	0.002	< 0.001	0.091	< 0.001	< 0.001	0.319	0.242	< 0.001	0.058
Prophylactic treatment line	0	12.4	4.6	13.6	17.2	16.9	37.5	71.8	25.8	27.6	46.5
	1	16.2	5.7	16.6	18.3	20.3	39.9	69.6	26.6	34.2	48.1
	2	18.0	5.7	18.9	21.0	20.1	44.9	72.8	29.9	40.1	52.7
	≥3	30.6	10.2	28.6	21.4	27.6	52.0	76.5	31.6	44.9	55.1
	p-value	< 0.001	0.011	< 0.001	0.138	< 0.001	< 0.001	0.155	0.182	< 0.001	0.027
Botulinum toxin prescription	no	12.9	4.8	14.0	17.4	17.4	37.9	71.7	26.0	28.6	46.8
	yes	32.1	9.4	28.3	22.6	15.1	54.7	73.6	43.4	52.8	56.6
	p-value	< 0.001	0.112	0.003	0.312	0.662	0.012	0.755	0.004	< 0.001	0.152

ISSN: 1129-2377